Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase Ib Open-Label Study Evaluating the Safety and Efficacy of NKTR-255 in Combination With CD19-Directed CAR-T Cell Therapy in Patients With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05359211
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:11.087997+00:00
Published At
2026-03-20T00:00:00+00:00
Record Updated At
2026-03-20
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent Grade 3b Follicular Lymphoma", "Recurrent Primary Mediastinal Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory Grade 3b Follicular Lymphoma", "Refractory Primary Mediastinal Large B-Cell Lymphoma", "Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-03-20"
protocolSection.identificationModule.nctId
"NCT05359211"
protocolSection.identificationModule.officialTitle
"A Phase Ib Open-Label Study Evaluating the Safety and Efficacy of NKTR-255 in Combination With CD19-Directed CAR-T Cell Therapy in Patients With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Recurrent Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified (protocolSection.conditionsModule.conditions)
  • Recurrent Grade 3b Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Primary Mediastinal Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified (protocolSection.conditionsModule.conditions)
  • Refractory Grade 3b Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Primary Mediastinal Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.